Recombinant assay for serodiagnosis of lyme disease regardless of OspA vaccination status

Maria Gomes-Solecki, G. P. Wormser, M. Schriefer, G. Neuman, L. Hannafey, J. D. Glass, R. J. Dattwyler

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

All current seroassays using cultured Borrelia burgdorferi as their antigen source have been rendered obsolete by the recombinant OspA Lyme disease vaccine. OspA is the major outer surface protein expressed in cultured B. burgdorferi, and any seroassay that uses whole organisms as its antigen source cannot differentiate between subjects who received the vaccine and those who were naturally infected. We developed a new sensitive and specific enzyme-linked immunosorbent assay (ELISA) utilizing recombinant chimeric borrelia proteins devoid of OspA (rNon-OspA) that can be used to detect antibodies to diagnostically important B. burgdorferi antigens in both OspA-vaccinated and nonvaccinated individuals. We tested sera from patients with Lyme disease and with conditions associated with false-positive serologies, OspA-vaccinated individuals, and healthy high-risk workers from an area of endemicity and normal sera from individuals from areas of nonendemicity. The rNon-OspA test was compared with two commercially available whole-cell immunoassays. The rNon-OspA assay is as sensitive and specific as the whole-cell assay (P > 0.05) for detection of anti-B. burgdorferi antibodies. However, the rNon-OspA assay can differentiate between populations comprised of naturally infected and OspA-vaccinated individuals (P < 0.05). Our data demonstrate that this new sensitive rNon-OspA ELISA can be used for the laboratory detection of B. burgdorferi antibodies regardless of vaccination status and could replace existing serologic assays for Lyme disease.

Original languageEnglish (US)
Pages (from-to)193-197
Number of pages5
JournalJournal of Clinical Microbiology
Volume40
Issue number1
DOIs
StatePublished - Jan 12 2002

Fingerprint

Borrelia burgdorferi
Lyme Disease
Serologic Tests
Vaccination
Antigens
Antibodies
Lyme Disease Vaccines
Enzyme-Linked Immunosorbent Assay
Recombinant Fusion Proteins
Borrelia
Serology
Serum
Immunoassay
Membrane Proteins
Vaccines
Population

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)

Cite this

Recombinant assay for serodiagnosis of lyme disease regardless of OspA vaccination status. / Gomes-Solecki, Maria; Wormser, G. P.; Schriefer, M.; Neuman, G.; Hannafey, L.; Glass, J. D.; Dattwyler, R. J.

In: Journal of Clinical Microbiology, Vol. 40, No. 1, 12.01.2002, p. 193-197.

Research output: Contribution to journalArticle

Gomes-Solecki, Maria ; Wormser, G. P. ; Schriefer, M. ; Neuman, G. ; Hannafey, L. ; Glass, J. D. ; Dattwyler, R. J. / Recombinant assay for serodiagnosis of lyme disease regardless of OspA vaccination status. In: Journal of Clinical Microbiology. 2002 ; Vol. 40, No. 1. pp. 193-197.
@article{ae18dfde15d3429d90e04c35175a39fa,
title = "Recombinant assay for serodiagnosis of lyme disease regardless of OspA vaccination status",
abstract = "All current seroassays using cultured Borrelia burgdorferi as their antigen source have been rendered obsolete by the recombinant OspA Lyme disease vaccine. OspA is the major outer surface protein expressed in cultured B. burgdorferi, and any seroassay that uses whole organisms as its antigen source cannot differentiate between subjects who received the vaccine and those who were naturally infected. We developed a new sensitive and specific enzyme-linked immunosorbent assay (ELISA) utilizing recombinant chimeric borrelia proteins devoid of OspA (rNon-OspA) that can be used to detect antibodies to diagnostically important B. burgdorferi antigens in both OspA-vaccinated and nonvaccinated individuals. We tested sera from patients with Lyme disease and with conditions associated with false-positive serologies, OspA-vaccinated individuals, and healthy high-risk workers from an area of endemicity and normal sera from individuals from areas of nonendemicity. The rNon-OspA test was compared with two commercially available whole-cell immunoassays. The rNon-OspA assay is as sensitive and specific as the whole-cell assay (P > 0.05) for detection of anti-B. burgdorferi antibodies. However, the rNon-OspA assay can differentiate between populations comprised of naturally infected and OspA-vaccinated individuals (P < 0.05). Our data demonstrate that this new sensitive rNon-OspA ELISA can be used for the laboratory detection of B. burgdorferi antibodies regardless of vaccination status and could replace existing serologic assays for Lyme disease.",
author = "Maria Gomes-Solecki and Wormser, {G. P.} and M. Schriefer and G. Neuman and L. Hannafey and Glass, {J. D.} and Dattwyler, {R. J.}",
year = "2002",
month = "1",
day = "12",
doi = "10.1128/JCM.40.1.193-197.2002",
language = "English (US)",
volume = "40",
pages = "193--197",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Recombinant assay for serodiagnosis of lyme disease regardless of OspA vaccination status

AU - Gomes-Solecki, Maria

AU - Wormser, G. P.

AU - Schriefer, M.

AU - Neuman, G.

AU - Hannafey, L.

AU - Glass, J. D.

AU - Dattwyler, R. J.

PY - 2002/1/12

Y1 - 2002/1/12

N2 - All current seroassays using cultured Borrelia burgdorferi as their antigen source have been rendered obsolete by the recombinant OspA Lyme disease vaccine. OspA is the major outer surface protein expressed in cultured B. burgdorferi, and any seroassay that uses whole organisms as its antigen source cannot differentiate between subjects who received the vaccine and those who were naturally infected. We developed a new sensitive and specific enzyme-linked immunosorbent assay (ELISA) utilizing recombinant chimeric borrelia proteins devoid of OspA (rNon-OspA) that can be used to detect antibodies to diagnostically important B. burgdorferi antigens in both OspA-vaccinated and nonvaccinated individuals. We tested sera from patients with Lyme disease and with conditions associated with false-positive serologies, OspA-vaccinated individuals, and healthy high-risk workers from an area of endemicity and normal sera from individuals from areas of nonendemicity. The rNon-OspA test was compared with two commercially available whole-cell immunoassays. The rNon-OspA assay is as sensitive and specific as the whole-cell assay (P > 0.05) for detection of anti-B. burgdorferi antibodies. However, the rNon-OspA assay can differentiate between populations comprised of naturally infected and OspA-vaccinated individuals (P < 0.05). Our data demonstrate that this new sensitive rNon-OspA ELISA can be used for the laboratory detection of B. burgdorferi antibodies regardless of vaccination status and could replace existing serologic assays for Lyme disease.

AB - All current seroassays using cultured Borrelia burgdorferi as their antigen source have been rendered obsolete by the recombinant OspA Lyme disease vaccine. OspA is the major outer surface protein expressed in cultured B. burgdorferi, and any seroassay that uses whole organisms as its antigen source cannot differentiate between subjects who received the vaccine and those who were naturally infected. We developed a new sensitive and specific enzyme-linked immunosorbent assay (ELISA) utilizing recombinant chimeric borrelia proteins devoid of OspA (rNon-OspA) that can be used to detect antibodies to diagnostically important B. burgdorferi antigens in both OspA-vaccinated and nonvaccinated individuals. We tested sera from patients with Lyme disease and with conditions associated with false-positive serologies, OspA-vaccinated individuals, and healthy high-risk workers from an area of endemicity and normal sera from individuals from areas of nonendemicity. The rNon-OspA test was compared with two commercially available whole-cell immunoassays. The rNon-OspA assay is as sensitive and specific as the whole-cell assay (P > 0.05) for detection of anti-B. burgdorferi antibodies. However, the rNon-OspA assay can differentiate between populations comprised of naturally infected and OspA-vaccinated individuals (P < 0.05). Our data demonstrate that this new sensitive rNon-OspA ELISA can be used for the laboratory detection of B. burgdorferi antibodies regardless of vaccination status and could replace existing serologic assays for Lyme disease.

UR - http://www.scopus.com/inward/record.url?scp=0036136432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036136432&partnerID=8YFLogxK

U2 - 10.1128/JCM.40.1.193-197.2002

DO - 10.1128/JCM.40.1.193-197.2002

M3 - Article

VL - 40

SP - 193

EP - 197

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 1

ER -